Neurosense Therapeutics Ltd (NRSN) Stock Analysis
Verdict: AVOID
Clinical potential in ALS/Alzheimer's is overshadowed by a terminal cash crunch and imminent massive dilution risk.
Investment score: 38/100
Analysis as of
Is Neurosense Therapeutics Ltd stock worth reviewing? AI model thesis
Avoid due to immediate insolvency risk despite positive Alzheimer's biomarker data.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 75/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Neurosense Therapeutics Ltd opportunities and risks
What speaks for NRSN
- Positive Alzheimer's Biomarker Data
What speaks against NRSN
- Zero Cash Runway / Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| NRSN | n/a | 0.0x | n/a | 0.0% | 0.0% | -0.0% |
| PLRZ | n/a | 0.0x | n/a | 0.0% | 0.0% | -27.1% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -27.1% |
Frequently asked questions about Neurosense Therapeutics Ltd (NRSN)
Is NRSN stock a good investment?
The cached TradeMates AI model rates Neurosense Therapeutics Ltd as AVOID with an investment score of 38/100. Avoid due to immediate insolvency risk despite positive Alzheimer's biomarker data. This is algorithmic model output, not personal investment advice.
Is NRSN stock a buy?
The TradeMates model verdict for NRSN is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.